Prevention of infections directly reduces the need for antibiotics and prophylactic vaccines have never induced resistance. Absynth’s vaccines target Staphylococcus aureus and Clostridium difficile, the cause of damage to health or death. Absynth is competitively placed with a suite of novel protein vaccine antigens that differ from and offer possible benefits over competitor products.
News & Discussions
Absynth Biologics involved with International Business Festival 2018 launch
Fiona Marston, Absynth Biologics CEO talks as part of the IBC 2018.
02/10/17
Comments are closed.